NCT00764582终止4 期
A Randomized, Observer-masked, Parallel-group, Multicenter Trial Evaluating the Ocular Penetration of 1.5% Levofloxacin Ophthalmic Solution and 0.5% Moxifloxacin Ophthalmic Solution in Subjects Undergoing Corneal Transplant Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- Santen Inc.
- 入组人数
- 60
- 主要终点
- Concentration of levofloxacin and moxifloxacin in the corneal tissue
研究概览
简要总结
Compare the corneal penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing penetrating keratoplasty (PK)
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
干预措施: 1.5% levofloxacin ophthalmic solution (Drug)
2
Active Comparator
干预措施: 0.5% moxifloxacin ophthalmic solution (Drug)
结局指标
主要结局
Concentration of levofloxacin and moxifloxacin in the corneal tissue
时间窗: Time of surgery
次要结局
- Adverse Events(4 days)
研究者
相似试验
已完成
4 期
Study of Ocular Penetration of Topically Administered FluoroquinolonesCataract ExtractionNCT00924729Johns Hopkins University50
已完成
4 期
Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active ComparatorCataractNCT00630019Santen Inc.96
已完成
不适用
Vitreous concentration of moxfloxacin and bacterial isolation during vitreous surgeryVitreoretinal diseasesJPRN-UMIN000001942Osaka University Hospital, Department of Ophthalmology80
已完成
3 期
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIsInfectious DiseasesNCT00828971Bayer16
尚未招募
不适用
Effect of Moxifloxacin(0.5mg) instillation in anterior chamber in Phacoemulsification surgeryCTRI/2020/06/025909Mohit kumar